A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
Studies have shown that the study drug, pembrolizumab, works by helping the immune system.
In this way, pembrolizumab may help to slow the growth of melanoma or may cause cancer cells
to die. Compared to standard treatments, pembrolizumab seems to lengthen the time patients
lived overall and the time without their cancer getting worse.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society